Devera Pine


Bone-Targeted Therapies Evolve in Prostate Cancer

May 13th 2013

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.

Using the New Therapeutic Options in Multiple Myeloma

April 5th 2013

There have been waves of advancements in the treatment of multiple myeloma and further exploration of existing regimens and research into novel therapeutics hold the promise of advances.

Colorectal Cancer Prognosis and Response to Chemotherapy Vary by Molecular Subtype

January 24th 2013

Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.

Novel Formulations and Molecular Characterization of AML Offer Hope and Complexity

January 10th 2013

Recent advances in the characterization of the molecular genetic defects underlying AML, as well as in novel formulations of therapies, are offering hope for improved outcomes.

Choosing a Tyrosine Kinase Inhibitor in Chronic Myelogenous Leukemia

December 19th 2012

The introduction of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia has dramatically changed the course of the disease.

Amid Setbacks, Efforts to Target Aurora Kinases Persist

November 1st 2012

The development of targeted agents aimed at aurora kinases has proceeded slowly, and the future may lie in combination therapies.

Bone Health Programs in Urology Practices Deliver Continuity of Care

July 12th 2012

Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.

Docetaxel in Combination With Novel Therapies in Prostate Cancer: Promising Phase III Trials Ongoing

May 29th 2012

To date, no studies of novel therapies combined with docetaxel and prednisone have demonstrated improvement in their designated endpoints. However, several promising combination trials are ongoing.

Adjuvant Chemotherapy in Breast Cancer-Or Not?

April 3rd 2012

Adjuvant chemotherapy improves disease-free and overall survival in many--but not all--patients with breast cancer.

Targeted Therapies in Breast Cancer Offer Increasing Hope and Complexity

April 2nd 2012

As research progresses, optimal treatment of breast cancer will involve individualization of therapy to focus on specific targets driving each patient's cancer.